Page 211«..1020..210211212213..220230..»

Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character – Giant Freakin Robot

Posted: September 16, 2022 at 2:59 am

By Michileen Martin| Published 2 days ago

According to Star Trek: Strange New Worlds actress Rebecca Romijn, if her Trek hero Una Chin-Riley needs a sympathetic ear while Starfleet has her locked up in between seasons, maybe her old Marvel character can come by to listen to her woes. Romijn recently joined her castmates at the 56-Year Mission Star Trek convention in Las Vegas, where she talked about the two characters shes best known for. The actress old fans that her Strange New Worlds character and the Brotherhoods Mystiquewho she played in the X-Men filmsshare some uncanny (we apologize for nothing) similarities.

As reported by TrekMovie, Romijn commented on the similarity between her Star Trek and Marvel roles when asked a question about the upcoming Season 2 of Strange New Worlds. What also is really strange about it, and I probably shouldnt say this, but I kept going back to when I was playing Mystique as a mutant, Romijn mused. I had little bits of dialogue in season 2 that were literally word-for-word things I said in theX-Menseries before. But they are related. They are two characters, and I relate them.

If youve watched Season 1 of Star Trek: Strange New Worlds, then you can probably guess the nature of the similarities between Una and Romijns Marvel character. Early in the inaugural season of Strange New Worlds, we learn that Una is secretly an Illyrian; a race of genetically-engineered people, and the genetically-engineered are not allowed within a hundred light years of Starfleet service. Season 1 ends on a cliffhanger, with Unas heritage somehow being discovered and Captain Pikes (Anson Mount) First Officer being arrested by Starfleet.

The parallels between Star Treks Una and Marvels Mystiqueor any of Marvels mutantsseem pretty clear. Like Mystique, Una is being attacked for her heritage, and for being different.

Though its still a little surprising for Romijn to say Una and Mystique share word-for-word dialogue. While Jennifer Lawrences version of the character has a lot more to say, Romijns version doesnt speak often and when she does, shes usually speaking through one of her many disguises and in someone elses voice. Considering how sparse her actual dialogue was in the films, its conceivable the lines shared between the characters was no accident.

It will be interesting to see how Romijns Star Trek characters story is resolved in the seasons of Strange New Worlds to come. Throughout Treks narrative, the ban on genetic engineering is often depicted as the last remaining prejudice of the otherwise utopian Federation. But we know Unas story wont end with the Federation doing away with that prejudice, because a century laterin Star Trek: Deep Space Ninewhen the genetic alterations Julian Bashir (Alexander Siddig) was forced to endure as a child are uncovered, that engineering is still illegal in the Federation and Bashir almost loses everything because of it.

We also know that Una Chin-Riley cant remain on Strange New Worlds forever since the showrunner hopes to take the story into the timeline of Star Trek: The Original Series, and Unas character was off the ship by then. Not to mention that when the Season 1 finale gave us a glimpse into a possible future, it showed us the Enterprise without Una. Whether or not Romijns Star Trek and Marvel characters ultimately share the same fate remains to be seen.

The rest is here:
Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot

Posted in Genetic Engineering | Comments Off on Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character – Giant Freakin Robot

Inside the controversial plan to bring extinct animals back from the dead – The Independent

Posted: September 16, 2022 at 2:59 am

Around 2,000 BC about the time the Egyptian pharaoh Mentuhotep was forming the Middle Kingdom a woolly mammoth died on a remote island in what is now Siberia.

This was no ordinary mammoth, however: this was the very last mammoth to ever live. With its death, the species would descend the irreversible River Styx of extinction, never again to be seen outside of the underworld.

Or maybe not.

A team of scientists with the biotechnology company Colossal, founded in part by Harvard geneticist George Church and backed by investors like the Winklevoss twins and actor Chris Hemsworth, now claim that they can resurrect the woolly mammoth, bringing the giants back to the tundra for the first time in 4,000 years.

The mammoth isnt alone, either. Colossal has also announced plans to revive the thylacine, an extinct Australian carnivore and other scientists are attempting to bring back species like the passenger pigeon, a once-legendary North American bird, in a process some are calling de-extinction.

Proponents claim that de-extinction can restore long-lost species to their rightful and important places in the ecosystem, and maybe undo some of the harm extinction has inflicted on the natural world.

But sceptics of de-extinction question what kind of animals this technology might really create and whether species resurrection could create new problems for the worlds still-living wildlife.

Im not convinced its a good idea, de-extinction, Tom Gilbert, an evolutionary biologist at the University of Copenhagen, tells The Independent.

But Im very fascinated by, at least, what could be done.

In Jurassic Park, scientists sequenced dinosaur DNA gathered from long-dead mosquitos, using that reconstructed genetic code to hatch a Tyrannosaurus rex.

There are some plot holes in that version of de-extinction mainly that DNA breaks down pretty quickly, so theres not much to sequence from 65-million-year-old fossils.

With something like a woolly mammoth, however, that concept is somewhat less far-fetched. Since mammoths lived relatively recently and in the cold, frozen north some specimens have been preserved, buried underground in the depths of the tundra, keeping parts of the species DNA intact.

As a result, scientists can sequence a good amount, if not all, of the mammoths genome. Colossal CEO Ben Lamm tells The Independent that the company expects to have about 90 per cent of the woolly mammoths genome.

The company plans to use cells from living Asian Elephants, the mammoths closest living relative, as a base template to try and recreate some of the mammoths quintessential traits, like shaggy hair and small ears, Mr Lamm says.

Turning a cell into a mammoth would require a lot more than just editing some genes, however youd need to turn that cell into a living, breathing, multi-tonne animal. So Mr Lamm says that the companys scientists are researching everything from stem cells and cellular engineering to embryo development and animal husbandry.

But why create a mammoth in the first place? One reason, according to the company, is the climate crisis.

Permafrost (permanently frozen ground) in the far northern tundra contains a ton of carbon. But as the world warms up from all the carbon that humans have dumped into the atmosphere, that permafrost is melting potentially releasing even more carbon into the atmosphere and creating a dangerous warming feedback loop.

Colossal says that if mammoths were re-introduced to the landscape, all their trampling could transform the tundra from forests and wetlands to grasslands. Since grasslands are lighter-coloured than forests and wetlands, the theory is that the ground would absorb less sunlight helping to keep the permafrost cold and all that stored carbon buried underground.

Colossal also has plans to resurrect the thylacine, also known as the Tasmanian tiger, an extinct carnivore seen here in captivity around 1930

(Getty Images)

Ecological restoration is also the goal for Revive and Restore, a non-profit organization aiming to bring back the passenger pigeon, a North American bird hunted to extinction in the early 20th century.

The passenger pigeon was the chief ecosystem engineer of eastern North American woodlands, Ben Novak, Revive and Restores lead scientist, tells The Independent.

The group says that the passenger pigeon which once congregated in flocks of hundreds of thousands of birds, dominating eastern North American landscapes in deafening and endless hordes used to disturb forests enough that they needed to regrow over time. In every stage of that regrowth were niches for wildlife like insects, mammals and other birds.

There are a lot of steps that need to go right for these plans to work. For one, these scientists would need to successfully create a viable, healthy animal that resembles a passenger pigeon or a mammoth using gene editing and cloning. Then, theyd need to successfully release enough of them into the wild and the animals would have to act as expected to get the ecological benefits the teams are hoping for.

But there are more conceptual questions about de-extinction, too. Since scientists will likely never fully sequence the mammoths genome parts of it will likely be forever lost to history these animals may never be exact replicas of the ancient beasts, no matter how well the gene editing and cloning might go.

Mr Lamm acknowledges that the company isnt trying to create duplicates of extinct animals. Were not cloning mammoths, were not creating exact copies of mammoths or exact copies of thylacines, he says. Instead, he says, theyre creating functional mammoths animals that will occupy the same ecological space that mammoths once did.

Success depends on your definition of de-extinction, Dr Gilbert says.

If your definition is to make a hairy elephant and keep it in a zoo, and thats what youre doing, and thats what you do, thats a success, right? Dr Gilbert says. But thats not the same as making a fully functional mammoth.

Dr Gilbert says that for him, the most interesting part of de-extinction is the research its based on. By taking elephant cells and trying to create a mammoth, the scientists are essentially trying to turn one animal into another animal, he notes itself a wild concept.

Some de-extinction projects arent even using genetic engineering at all. A project in South Africa, for example, is trying to recreate the quagga a type of zebra hunted to oblivion in the 19th century by selectively breeding other zebras to create an animal that looks like the quagga.

If it looks like a passenger pigeon, behaves like a passenger pigeon, you know its a passenger pigeon, Mr Novak says, referencing the old saw about ducks.

The passenger pigeon used to gather in massive flocks, dominating the North American skies before being hunted to extinction

(Getty Images)

But, of course, there are 300 types of ducks in the world. And geese look like ducks, and theyre not ducks, Mr Novak adds. We know theres subtlety to that, we will always know that the new passenger pigeons are not the original passenger pigeons.

Yet from an ecological perspective, that distinction doesnt matter, he says.

If it functions and does well in the ecosystem, Im happy to say that weve recreated the passenger pigeon, Mr Novak says.

Dr Gilbert also points out that if the public believes extinct species can simply be resurrected, that could create problems for currently endangered but not yet extinct species.

Suppose some mining company wanted to dig up a huge section of the Amazon rainforest, he suggests. Companies are often barred from ripping apart an ecosystem like that because people understand that many species will go extinct if we destroy their habitats, he adds.

If people think we can flip a switch and bring animals back from the dead, they might be less motivated by these concerns, Dr Gilbert surmises.

That could be especially true if people dont understand that de-extinction at least in its current form is massively time- and money-intensive and has yet to be truly successful for any singular species, let alone the thousands of species you might lose by cutting down the rainforest.

Mr Lamm said this was more of an education problem. He also notes that some of Colossals research including on things like in vitro fertilization and disease treatments in elephants could be applied to modern-day animals.

And the same argument about public perception could be made for animals kept in captivity, Mr Novak argues. Its literally the most negligible concern over all this, he says.

In another sense, Mr Novak says, that argument is just the continuation of the challenge wildlife conservationists have been facing for decades.

De-extinction is the extension of something that conservation has been doing for nearly 200 years, he says.

In ecosystems around the world, conservationists have restored long-lost wildlife to the ecosystem like wolves in Yellowstone National Park or beavers in Europe. The only difference is that none of these species had been entirely extinct and whether we can make that leap remains to be seen.

For me, its always been a conservation-, ecological restoration-driven discipline, he says. And will remain that way the rest of my life.

More here:
Inside the controversial plan to bring extinct animals back from the dead - The Independent

Posted in Genetic Engineering | Comments Off on Inside the controversial plan to bring extinct animals back from the dead – The Independent

The science behind the oil supply breakdown in ‘Last Light’ – Syfy

Posted: September 16, 2022 at 2:59 am

We havent seen Matthew Fox in a TV series since Lost ended in 2010. Now, Fox has returned as the protagonist of Last Light, a show developed from Alex Scarrows novel of the same name. Last Light is now streaming on Peacock. Minor spoilers below.

The story opens on chemist Andy Yeats played by Fox as hes called away to handle an oil emergency just before his son is set to undergo experimental eye surgery. Yeats arrives at the refinery site where he discovers something is wrong with the oil. At the same time, the world is pockmarked by blackouts. Its soon revealed that the worlds oil supplies have been corrupted as part of a coordinated attack.

The world immediately falls into a state of progressive chaos. With supply chain issues, climate change, and the ongoing transition to alternative renewable fuel sources, we cant help but wonder what might actually happen of the oil supply chains were severed.

In the show, the effects of oil supply disruption are felt right away. Planes fall out of the sky and ships flounder in the water. Its clear, whatever the source of the attack, it isnt happening only at the source. All of the worlds oil is contaminated, even the oil youre currently using. Where that to happen, wed all know pretty quickly. Its hard to power almost anything these days without a working supply of oil, for better or for worse.

Electric vehicles would keep working, but probably only as long as their batteries lasted. Thats because power plants largely use fossil fuels to generate power. Even those which dont are pretty reliant on the rest of the global supply chain, which would break down if oil were immediately withheld.

The good news is that likely wouldnt happen. If the worlds oil deposits suddenly dried up today, wed be in trouble, but wed have at least some cushion. Although, not much of one. At present, its estimated that the United States has something like 700 million barrels of oil stockpiled in the Strategic Petroleum Reserve, a series of underground caves in Texas and Louisiana.

The bad news is the United States oil consumption sits at around 20 million barrels per day. At current consumption levels, wed tap out our strategic reserves in a little over a month. Of course, most of that would probably be routed to strategic destinations and most of us would experience severe oil rations in an attempt to extend the reserves lifespan.

Countries around the world have similar stockpile programs which could stem the bleeding in the event of a supply breakdown. The fact remains, however, that wed have to find a solution quickly or risk the machinery which keeps our society functioning shutting down.

Unless we take concerted steps toward transitioning to a more diverse energy profile, even a best-case scenario would cause our societies to stumble once global oil supplies are cut off.

Its unlikely. Most oil is held in deposits underground and discretely separated from other oil reserves. Any intentional attack would require a level of coordination never before seen. The antagonists of such a story would need to introduce a contaminant at every reserve all at the same time. Manually introducing a contaminant that would render oil unusable probably isnt feasible. Unless, of course, its an act of nature.

Nature is very good at exploiting resources and by tapping into underground oil deposits we have exposed vast stores of material that are definitionally highly energetic. Theyd make an ample food supply for the right organism.

In the show, Yeats learns early on that the characteristics of the oil samples arent right. Among other things, the viscosity is out of normal ranges. Importantly, the viscosity of oil is important to its proper functioning as either a lubricant or a propellant. If you could introduce an organism that somehow changes the properties of the oil, its possible that organism could spread across the globe and impact the entire supply. Although, getting the timing right would be a challenge.

Theres some evidence this sort of strategy might actually work. A study published in the journal Energy Sourcesinvestigated the results of introducing various microorganisms including Pseudomonas aeruginosa, Bacillus subtilis, and Klebsiella spp to crude oil. After introduction, scientists measured the viscosity of the intentionally contaminated oil compared to a control sample.

After only three minutes, the viscosity of the crude oil was reduced by more than 50 percent. In the wake of genetic engineering, one can imagine a situation in which an organism is engineered to chew through oil wherever it is found, changing it so substantially that it becomes unusable. Once it came into contact with oil anywhere, whether in the ground or in your car, it might be able to multiply rapidly, on timescales shorter than what it takes to run your errands.

An uncontrolled organism would be incredibly difficult to get our arms around quickly enough to prevent the worst effects. Theres no single point of failure, its a war wed have to fight on all fronts, perhaps through the engineering of another organism to prey on or outcompete the threat.

Of course, the likelihood of any of this occurring is slim, better suited for the screen than the streets. Still, it might be worth putting a little extra emphasis on transitioning away from fuels susceptible to biological attack.

It's a fan thing

Join SYFY Insider to get access to exclusive videos and interviews, breaking news, sweepstakes, and more!

Sign Up for Free

See more here:
The science behind the oil supply breakdown in 'Last Light' - Syfy

Posted in Genetic Engineering | Comments Off on The science behind the oil supply breakdown in ‘Last Light’ – Syfy

Scientists closer to making blood stem cells in the lab – Cosmos

Posted: September 16, 2022 at 2:59 am

Two new pieces of research out of the University of NSW in Sydney have shone new light on how the precursors to blood stem cells occur in animals and humans, and how they may be induced artificially.

In a study published in Cell Reports, researchers demonstrated how a simulation of an embryos beating heart, using a microfluidic device in the lab, led to the development of human haematopoietic or blood stem cells.

A second study in Nature Cell Biology, revealed the cells in mice embryos that are responsible for blood stem cell creation within the aorta.

Both studies are significant steps towards understanding how, when, where and which cells are involved in the creation of blood stem cells, which could one day eliminate the need for blood transfusions or stem cell transplantation from donors.

Haematopoietic or blood stem cells are the cells that give rise to all other blood cells from white and red blood cells to platelets and more in a process called haematopoiesis. Haematopoietic stem cell transplants are often performed for some cancer patients, after treatment (such as chemotherapy and radiation therapy) kills the patients own stem cells.

Scientists have been attempting to make blood stem cells in the lab to solve the problem of donor blood stem cell shortages for the last few decades.

Blood stem cells used in transplantation require donors with the same tissue-type as the patient, says senior author of the Cell Reports study Robert Nordon, associate professor inthe Graduate School of Biomedical Engineering.

Manufacture of blood stem cells from pluripotent stem cell lines would solve this problem without the need for tissue-matched donors, providing a plentiful supply to treat blood cancers or genetic disease.

Pluripotent stem cells have the capacity to produce many different types of cells, including blood stem cells, but can only be sourced from animal or human embryos. On the other hand, induced pluripotent stem cells are generated directly from somatic cells adult cells that have already differentiated into their cell type through genetic manipulation.

But scientists still have a lot to learn about how to do it safely in the lab.

Get an update of science stories delivered straight to your inbox.

Scientists already knew that endothelial cells lining the aorta in the heart change into blood stem cells in embryonic development.

Part of the problem is that we still dont fully understand all the processes going on in the microenvironment during embryonic development that leads to the creation of blood stem cells at about day 32 in the embryonic development, says first author of the Cell Reports study Dr Jingjing Li, apostdoctoral fellow at the Graduate School of Biomedical Engineering.

So we made a device mimicking the heart beating and the blood circulation and an orbital shaking system which causes shear stress or friction of the blood cells as they move through the device or around in a dish.

Not only did the 3cm by 3cm microfluidic device create blood stem cell precursors that went on to undergo haematopoiesis and differentiate into different blood cells, but it also created the tissue cells of the embryonic heart environment that are crucial to this process.

What weve shown is that we can generate a cell that can form all the different types of blood cells. Weve also shown that it is very closely related to the cells lining the aorta so we know its origin is correct and that it proliferates, says Nordon.

We are working on up-scaling manufacture of these cells using bioreactors, says Li.

Researchers from UNSW Medicine and Health were also doing their own research in mice to identify the cells that regulate this process.

They found that cells known as Mesp1-derived PDGFRA+ stromal cells can convert both embryonic and adult endothelial cells into blood cells.

While more research is needed before this can be translated into clinical practice including confirming the results in human cells the discovery could provide a potential new tool to generate functioning haematopoietic cells.

Using your own cells to generate blood stem cells could eliminate the need for donor blood transfusions or stem cell transplantation. Unlocking mechanisms used by nature brings us a step closer to achieving this goal, says co-senior author of the Nature Cell Biology paper Professor John Pimanda, from the Prince of Wales Clinical School at UNSW Sydney.

View post:
Scientists closer to making blood stem cells in the lab - Cosmos

Posted in Genetic Engineering | Comments Off on Scientists closer to making blood stem cells in the lab – Cosmos

Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight – Digital Journal

Posted: September 16, 2022 at 2:59 am

Oncolytic Cancer Therapies Market

The Oncolytic Virus Therapies market is expected to show positive growth in the forecast period (20222032) due to the increased prevalence, randomized, controlled non-crossover trials with potential benefits. Some of the main reasons for this novel therapys insignificant revenues are its limitations, no statistically significant benefit in overall survival, and intense competition from immune checkpoint inhibitors due to their efficacy and manageable side effects.

DelveInsightsOncolytic Virus Therapies Market Insightsreport includes a comprehensive understanding of current treatment practices, Oncolytic Virus Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (theUnited Kingdom,Italy,Spain,France, andGermany),Japan].

Some facts of the Oncolytic Virus Therapies market report are:

Download the report to understand which factors are driving Oncolytic Virus Therapies market trends @Oncolytic Virus Therapies market forecast.

Oncolytic Virus Therapies Overview

Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. Oncolytic Virus Therapies is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.

Oncolytic Virus Therapies Epidemiology Segmentation

According to DelveInsight estimates, there were approximately 632K Oncolytic Virus Therapies targeted patient pool in the 7MM in 2021.

Among the 7MM countries, the US had the highest incidence of Oncolytic Virus Therapies in 2021.

The Oncolytic Virus Therapies market report proffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving Oncolytic Virus Therapies epidemiology trends @Oncolytic Virus Therapies Epidemiological Insights.

Oncolytic Virus Therapies Pipeline Therapies and Key Companies

Learn more about the Oncolytic Virus Therapiestherapies in clinical trials @Drugs forOncolytic Virus Therapies Treatment

Oncolytic Virus Therapies Market Dynamics

Oncolytic viruses have many advantages over other tumor immunotherapies, including high killing efficiency, precise targeting, fewer side effects or drug resistance, and low cost, fueling the oncolytic virus therapies market growth. Furthermore, as certain oncolytic viruses, such as Adeno oncolytic viruses, have demonstrated antitumor memory, they could be used as a cancer vaccine.

Scope of the Oncolytic Cancer Therapies Market Report

Discover more about emerging oncolytic cancer therapies in development @Oncolytic Cancer Therapies Clinical Trials

Table of Contents

1.

Oncolytic Virus Therapies MarketKey Insights

2.

Oncolytic Virus Therapies MarketReport Introduction

3.

Oncolytic Virus Therapies Market Overview at a Glance

4.

Oncolytic Virus Therapies MarketExecutive Summary

5.

Disease Background and Overview

6.

Oncolytic Virus TherapiesTreatment and Management

7.

Oncolytic Virus TherapiesEpidemiology and Patient Population

8.

Patient Journey

9.

Oncolytic Virus TherapiesEmerging Drugs

10.

7MMOncolytic Virus TherapiesMarket Analysis

11.

Oncolytic Virus TherapiesMarket Outlook

12.

Potential of Current and Emerging Therapies

13.

KOL Views

14.

Oncolytic Virus TherapiesMarket Drivers

15.

Oncolytic Virus TherapiesMarket Barriers

16.

Unmet Needs

17.

SWOT Analysis

18.

Appendix

19.

DelveInsight Capabilities

20.

Disclaimer

21.

About DelveInsight

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market

Read the rest here:
Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal

Posted in Genetic Engineering | Comments Off on Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight – Digital Journal

Don’t call it waste – it can be turned into hydrogen if you handle it right – Innovation Origins

Posted: September 16, 2022 at 2:59 am

Circularity is one way to help make the green transition happen. Now, everything can get a second life, and even what we used to consider trash can be a valuable resource. The same goes for industrial byproducts. If producing biogas and methane from organic trash is nothing new, that does not hold true for green hydrogen, which researchers are trying to produce from this kind of waste.

At the German Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) research is now focusing on producing carbon-negative hydrogen using biomass and plant residues. Scientists are exploring several HyBECCS (Hydrogen Bioenergy with Carbon Capture and Storage) approaches to get H2 from waste materials that would otherwise remain trash. From bacteria-based bioreactor treatments to thermochemical gasification approaches, the options are numerous.

The German Environment Agency reports that 15 million tonnes of organic waste is produced in the country including from household waste, agricultural waste and waste from food production. This portion either goes to composting plants or incinerators. The European Environment Agency also stressed the relevance of treating this waste properly in order to generate heat or produce sustainable fuels. So, getting hydrogen from waste would create added value.

In previous projects where waste from the food industry was converted to hydrogen, I was struck by how large the carbon dioxide fraction was. The main achievement was to produce a source of biogenic CO2that is a by-product of hydrogen production. This means that H2 can be used in a climate-neutral way and carbon dioxide can be stored, Johannes Full explains. He is head of the group Sustainable Development of Biointelligent Technologies at Fraunhofer IPA in Stuttgart.

Microbiologists are building bacteria that convert CO2 into food

Is your hamburger or protein shake going to be made out of CO2in the future? Yes, if its up to microbiologist Nico Claassens.

The proper management of organic waste helps to reduce emissions. When it is dumped in landfills, carbon dioxide and methane are released some of the major greenhouse gases that pollute the air. One of the main methods of processing waste in biological treatment facilities is anaerobic digestion which is an alternative to composting. It entails placing waste in a container devoid of air. Bacteria then break down the waste and allow methane to be captured, while the remaining matter can serve as a sustainable type of fertilizer.

In one of the approaches that Full and his team are experimenting with, so-called purple bacteria thats their color are the key players. These photosynthetic bacteria can convert agriculture and food industry waste into hydrogen. In other words, they can produce H2 through light. Professor Robin Ghoshs team from the Institute of Biomaterials and Biomolecular Systems at the University of Stuttgart found a way to grow this bacteria without light. This is a considerable breakthrough, as there is no need for more sophisticated photobioreactors to grow them, explains Full.

According to the researcher, one more year of research will help the concept move from a lab scale to a bigger one.

One other approach that researchers are currently testing is methane pyrolysis. This process converts biogas into hydrogen and solid carbon. As the ancient Greek etymology suggests literally dislodging with fire it involves the use of fire to dissolve the material. Moreover, this thermal decomposition occurs at over 500 degrees, without the presence of any air.

Full: On one hand, we get a gas fraction which contains hydrogen. On the other, we get solid carbon as a product. This makes storing it easier- no further conversion is needed.

With his team, hes experimenting a number of methods to get hydrogen out of biowaste.

Another avenue that the Fraunhofer team is currently testing is dark fermentation. This process can be viewed as one part of the whole biogas production procedure. Essentially, the same waste streams are fed into a bioreactor as is the case in the normal biowaste treatment procedure but for a shorter period of time. This ensures that hydrogen and carbon dioxide are not converted to methane.

The main disadvantage of this process is that we dont get a very high yield of hydrogen from it compared to other methods, Full emphasizes. On the flip side, its an energy-efficient procedure that can be done in standard bioreactors. It is an upgrade to biogas processing in that it provides another product in addition to biogas, which is hydrogen.

Full also cites the genetic manipulation of bacterial streams. According to him, genetic engineering will lead to bacteria behaving the way researchers want them to. Microorganisms will then play a role in either biohydrogen and HyBECCS processes or fermentation. Higher yields and better efficiency can be achieved this way. If we make bioprocesses more adaptable to waste by developing intelligent and self-adaptive control systems, we will arrive at even more efficient, biointelligent systems, the team leader adds.

Your weekly innovation overviewEvery sunday the best articles of the week in your inbox.

Food waste separation can be done with minor investment thats what a Lithuanian city is showing

Separating food waste is a relatively new practice in Lithuania. Dealing with it is one of the hardest tasks for municipalities particularly in the early stages.Since 2019, as per the national waste management plan, cities with over 50,000 inhabitants were required to start implementing a separate collection system for this waste.

The Stuttgart cohort also worked on a new model of a hydrogen-based economy. Industrial Hydrogen Hubs in Baden-Wrttemberg is the name of a study that showed the potential of green hydrogen to cover specific energy demands such as heavy goods traffic in the area. Specifically, several hydrogen production hubs were set up as part of the model. For the model to be successful, the strategic positioning of the hubs played a key role.

We thought about how to bring about hydrogen economies without having to overhaul the whole energy system. The basic premise was to think about decentralized production and use hubs through, for example, the use of biogas, photovoltaics, wind power or biogas plants. The next step was to find a local market where we wouldnt have to build a large infrastructure. This way, we wanted to prove that decentralized production is feasible. Then all of these nuclei can continue to grow towards the goal of a hydrogen economy, Full concludes.

Read the original here:
Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins

Posted in Genetic Engineering | Comments Off on Don’t call it waste – it can be turned into hydrogen if you handle it right – Innovation Origins

Stem Cell Transplantation: What it Is, Process & Procedure

Posted: September 16, 2022 at 2:58 am

OverviewWhat is a stem cell transplant?

Healthcare providers use stem cell transplants to treat people who have life-threatening cancer or blood diseases caused by abnormal blood cells. A stem cell transplant helps your body replace those blood cells with healthy or normal blood cells. If you receive a stem cell transplant, your provider may use your own healthy stem cells or donor stem cells.

Your blood cells come from stem cells in your bone marrow. Your bone marrow constantly creates new stem cells that become blood cells. Stem cell transplants can involve stem cells taken from bone marrow or from blood. Providers sometimes refer to stem cell and bone marrow transplants as haematopoietic stem cell transplants (HSCT). This article focuses on stem cells taken from blood.

Healthcare providers use stem cells to replace unhealthy blood cells that cause conditions such as several types of leukemia, lymphoma and testicular cancer. They also use transplanted stem cells to treat several types of anemia. Some people who have multiple sclerosis may benefit by receiving healthy stem cells. Researchers are investigating ways to treat other autoimmune diseases with stem cell transplants.

Healthcare providers typically use stem cell transplants to treat life-threatening cancer or blood diseases. Unfortunately, not everyone who has those conditions can have the procedure. Here are factors providers take into consideration:

Recently data reported nearly 23,000 people had stem cell transplants in 2018.

To understand how stem cell transplants work, it may help to know more about stem cells and their role in your body:

Healthcare providers obtain stem cells from several sources:

If youre a candidate for a stem cell transplant, your healthcare provider will perform the following tests to confirm youre physically able to manage transplantation processes, including pre-treatment chemotherapy called conditioning and transplantation side effects:

Before your blood tests, your provider may place a central venous catheter (CVC) in one of the large veins in your upper chest. CVCs are tubes that serve as central lines that providers use to take blood and provide medication and fluids. CVCs eliminate repeated needle sticks to draw blood or insert intravenous tubes throughout the transplantation process.

Transplant conditioning is intensive chemotherapy and/or radiation therapy that kills cancer cells in your bone marrow. Conditioning also kills existing blood cells.

If youre receiving your own stem cells, your provider may give you medication to boost your stem cell production. Theyll do follow-up blood tests to check on stem cell production.

If youre receiving your own stem cells, your providers will take blood so they can remove healthy stem cells for transplant. . To do that, they connect veins in both of your arms to a cell separator machine. The machine pulls your blood from one arm, filters the blood and then returns it to through your other arm. This process doesnt hurt. Providers may need to take blood more than once to ensure they have enough stem cells to transplant. The actual transplantation involves receiving your stem cells via your CVC.

Just like someone receiving their own cells, youll receive healthy stem cells via your CVC.

Your new stem cells will need time to produce new blood cells. If you received donor stem cells, your transplanted stem cells will replace unhealthy stem cells and begin to build a new immune system. This process is engraftment.

Either way, you may need to stay in or close to the hospital for several months so your healthcare providers can support your recovery and monitor your progress. Heres what you can expect after your stem cell transplant:

Successful stem cell transplants may help people when previous treatments dont slow or eliminate certain cancers.

The greatest risk is that youll go through the procedure and your transplanted stem cells cant slow or eliminate your illness.

Allogenic and autologous stem cell transplants have different complications. Allogenic stem cell transplants can result in graft versus host disease. This happens when your immune system attacks new stem cells. Potential complications will vary based on your overall health, age and previous treatment. If youre considering a stem cell transplant, your healthcare provider will outline potential complications so you can weigh those risks against potential benefits.

It can take several weeks to several months to recover from a stem cell transplant. Your healthcare provider may recommend you stay in or near the hospital or transplant center for the first 100 days after your procedure.

Its difficult to calculate an overall success rate. That said, the most recent data show the highest number of stem cell transplants involved people with multiple myeloma or Hodgkin and non-Hodgkin lymphoma who received autologous stem cell transplants. Here is information on three-year survival rates:

A successful stem cell transplant can change your life, curing your condition or slowing its growth. But its not an overnight transformation. It can take a year or more for you to recover. Here are some challenges and ways to overcome them:

You may have days when you feel exhausted and days when you feel fine. A hard day doesnt mean youre not doing well. It means you need to give yourself a break and take it easy.

Youll have regular follow-up appointments with your provider. But its important to remember your immune system likely will be weak for a year or so after your transplantation. Contact your provider right away if you develop any of the following symptoms:

A note from Cleveland Clinic

If youve been coping with cancer or a blood disease, a stem cell transplant can be a new lease on life. It can mean hope for a cure or remission when other treatments havent worked. But stem cell transplants come with demanding physical challenges and significant risks. Not everyone who has cancer or blood conditions is a candidate for a stem cell transplant. Unfortunately, not everyone who is a candidate but needs donor stem cells finds a donor. If youre considering a stem cell transplant, talk to your healthcare provider about potential risks and benefits. Theyll evaluate your situation, your options and potential outcomes.

See the original post here:
Stem Cell Transplantation: What it Is, Process & Procedure

Posted in Stem Cell Treatments | Comments Off on Stem Cell Transplantation: What it Is, Process & Procedure

‘Glass bubble’ nanocarrier boosts effects of combination therapy for pancreatic cancer – UCLA Newsroom

Posted: September 16, 2022 at 2:56 am

Key takeaways:

Over the past 30 years, progress in early detection and treatment of cancer has helped reduce the overall death rate by more than 30%. Pancreatic cancer, however, has remained difficult to treat. Only 1 in 9 people survive five years after diagnosis, in part because this cancer is protected by biological factors that help it resist treatment.

In hopes of turning the tide, UCLA researchers have developed a technology that delivers a combination therapy to pancreatic tumors using nanoscale particles loaded with irinotecan, a chemotherapy drug approved as part of a drug regimen for pancreatic cancer, and3M-052, an investigational drug that can boost immune activity and help overcome tumors resistance.

In a study recently published in the journal ACS Nano, the research team showed that the simultaneously delivered combination outperformed the sum of its parts in a mouse model of pancreatic cancer.

In my opinion, invoking the immune system will make a big difference in providing a much better treatment outcome for pancreatic cancer, said corresponding author Andr Nel, a distinguished professor of medicine and director of research at the California NanoSystems Institute at UCLA. Thats where I hope this research is taking us.

The researchers double-loaded nanocarrier was more effective at shrinking tumors and preventing cancer metastasis in mice than either irinotecan without a nanocarrier or nanocarriers that delivered the two drugs independently. The combination therapy also attracted more cancer-killing immune cells to tumor sites and maintained drug levels in the blood for longer. There was no evidence of harmful side effects.

In addition to blocking cancer cells from growing, irinotecan sends a danger signal to the immune systems dendritic cells; these in turn mobilize killer T cells, which travel to tumor sites and destroy cancer cells. But because dendritic cells are often functionally impaired in patients with pancreatic cancer, 3M-052 provides extra assistance, helping them better marshal killer T cells both at the cancer site and in nearby lymph nodes.

Combination therapies for cancer are not new, but packaging drugs together in the same nanocarrier has proven difficult. Only one dual-delivery nanocarrier for chemotherapy has been approved by the Food and Drug Administration. However, over the past seven years, the Nel lab has developed an approach for simultaneous delivery, and the current findings provide further evidence that their innovative nanocarrier design enables the drugs to work in tandem more effectively than if they were delivered separately.

Most nanocarriers are composed of layers of lipid molecules made up of fatty substances, similar to a cell membrane, with spaces into which drugs can be packaged. With the new device, that double layer of lipids surrounds a core glass bubble made of silica whose hollow interior can be filled with irinotecan. In an ingenious twist, UCLA postdoctoral researcher and first author Lijia Luo figured out that the 3M-052 molecules fatty tail could be used for integrating the second drug directly into these outer lipid layers.

The structural design of the carrier, which is so small that it would take 1,000 of them to span the width of a human hair, helps prevent drug leakage and toxicity while the device enters a formidable ropelike barrier protecting the pancreatic cancer and travels to the tumor site. The glass bubbles offer additional protection from leakage, enabling the carrier to deliver more irinotecan to the tumor site, compared to other drug carriers.

CNSI/UCLA

The nanocarrier's hollow glass bubble (white, at left) is packed with irinotecan (green) and is covered by lipid layers (blue) that contain the immue-boosing drug 3M-052 (orange particles in close-up image on right).

The team will conduct further preclinical experiments to test their treatment in large-animal models and confirm quality-control for large-scale manufacturing of their silica nanocarriers.

It traditionally takes 10 to 20 years for new breakthrough technologies to reach the marketplace, said Nel, who is also founder and chief of UCLAs nanomedicine division and director of the University of Californias Center for Environmental Implications of Nanotechnology. Nanocarriers have been around for almost 20 years. While lipid-based nanocarriers are leading the way, the silica-based carrier decorated with lipid layers stands a good chance of speeding up the rate of discovery and improving cancer immunotherapy.

Other co-authors of the study are research scientists Xiang Wang, Yu-Pei Liao and Chong Hyung Chang, all of UCLA.

The study was supported by the National Cancer Institute.

Read the original here:
'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom

Posted in Nano medicine | Comments Off on ‘Glass bubble’ nanocarrier boosts effects of combination therapy for pancreatic cancer – UCLA Newsroom

The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review – Cureus

Posted: September 16, 2022 at 2:56 am

Nanotechnology, nicknamed "the manufacturing technology of the twenty-first century," allows us to manufacture a vast range of sophisticated molecular devices by manipulating matter on an atomic and molecular scale. These nanomaterials possess the ideal properties of strength, ductility, reactivity, conductance, and capacity at the atomic, molecular, and supramolecular levels to create useable devices and systems in a length range of 1-100 nm. The materials' physical, chemical, and mechanical characteristics differ fundamentally and profoundly at the nanoscale from those of individual atoms, molecules, or bulk material, which enables the most efficient atom alignment in a very tiny space. Nanotechnology allows us to build various intricate nanostructured materials by manipulating matter at the atomic and molecular scale in terms of strength, ductility, reactivity, conductance, and capacity [1,2].

"Nanomedicine" is the science and technology used to diagnose, treat, and prevent diseases. It is also used for pain management and to safeguard and improve people's health through nanosized molecules, biotechnology, genetic engineering, complex mechanical systems, and nanorobots [3]. Nanoscale devices are a thousand times more microscopic than human cells, being comparable to biomolecules like enzymes and their respective receptors in size. Because of this property, nanosized devices can interact with receptors on the cell walls, as well as within the cells. By obtaining entry into different parts of the body, they can help pick up the disease, as well as allow delivery oftreatment to areas of the body that one can never imagine being accessible. Human physiology comprises multiple biological nano-machines. Biological processes that can lead to cancer also occur at the nanoscale. Nanotechnology offers scientists the opportunity to experiment on macromolecules in real time and at the earliest stage of disease, even when very few cells are affected. This helps in the early and accurate detection of cancer.

In a nutshell, the utility of the nanoscale materials for cancer is due to the qualities such as the ability to be functionalized and tailored to human biological systems (compatibility), the ability to offer therapy or act as a therapeutic agent, the ability to act as a diagnostic tool, the capability to penetrate various physiological barriers such as the blood-brain barrier, the capability to accumulate passively in the tumor, and the ability to aggressively target malignant cells.

Nanotechnology in cancer management has yielded various promising outcomes, including drug administration, gene therapy, monitoring and diagnostics, medication carriage, biomarker tracing, medicines, and histopathological imaging. Quantum dots (QDs) and gold nanoparticles are employed at the molecular level to diagnose cancer. Molecular diagnostic techniques based on these nanoparticles, such as biomarker discovery, can properly and quickly diagnose tumors. Nanotechnology therapeutics, such as nanoscale drug delivery, will ensure that malignant tissues are specifically targeted while reducing complications. Because of their biological nature, nanomaterials can cross cell walls with ease. Because of their active and passive targeting, nanomaterials have been used in cancer treatment for many years. This research looks at its applications in cancer diagnosis and therapy, emphasizing the technology's benefits and limitations [3-5]. The various uses of nanotechnology have been enumerated in the Table 1.

Early cancer detection is half the problem solved in the battle against cancer. X-ray, ultrasonography, CT, magnetic resonance imaging (MRI), and PET scan are the imaging techniques routinely used to diagnose cancer. Morphological changes in tissues or cells (histopathology or cytology) help in the final confirmation of cancer. These techniques detect cancer only after visible changes in tissues, by which time the cancer might have proliferated and caused metastasis. Another limitation of conventional imaging techniques is their failure to distinguish benign from malignant tumors. Also, cytology and histopathology cannot be employed as independent, sensitive tests to detect cancer at an early stage. With innovative molecular contrast media and materials, nanotechnology offers quicker and more accurate initial diagnosis, along with an ongoing assessment of cancer patient care [6].

Although nanoparticles are yet to be employed in actual cancer detection, they are currently being used in a range of medical screening tests. Gold nanoparticles are among the most commonly used in home test strips. A significant advantage of using nanoparticles for the detection of cancer is that they have a large surface area to volume ratio in comparison to their larger counterparts. This property ensures antibodies, aptamers, small molecules, fluorescent probes, polyethylene glycol (PEG), and other molecules cover the nanoparticle densely. This presents multiple binding ligands for cancer cells (multivalent effect of nanotools) and therefore increases the specificity and sensitivity of the bioassay [7,8]. Applications of nanotechnology in diagnosis are for the detection of extracellular biomarkers for cancer and for in vivo imaging. A good nanoprobe must have a long circulating time, specificity to the cancer tissue, and no toxicity to nearby tissue [9,10].

Detection of Biomarkers

Nanodevices have been studied to detect blood biomarkers and toxicity to healthy tissues nearby. These biomarkers include cancer-associated circulating tumor cells, associated proteins or cell surface proteins, carbohydrates or circulating tumor nucleic acids, and tumor-shed exosomes. Though it is well known that these biomarkers help to detect cancer at apreliminary stage, they also help to monitor the therapy and recurrence. They have limitations such as low concentrations in body fluids, variations in their levels and timings in different patients, and difficult prospective studies. These hurdles are overcome by nanotechnology, which offers high specificity and sensitivity. High sensitivity, specificity, and multiplexed measurements are all possible with nano-enabled sensors. To further illuminate a problem, next-generation gadgets combine capture with genetic analysis [11-15].

Imaging Using Nanotechnology

Nanotechnology uses nanoprobes that will accumulate selectively in tumor cells by passive or active targeting. The challenges faced are the interaction of nanoparticles with blood proteins, their clearance by the reticuloendothelial system, and targeting of tumors.Passive targeting suggests apreference for collecting the nanoparticles in the solid tumors due to extravasation from the blood vessels. This is made possible by the defective angiogenesis of the tumorwherein the new blood vessels do not have tight junctions in their endothelial cells and allow the leaking out of nanoparticles up to 150 nm in size, leading to a preferential accumulation of nanoparticles in the tumor tissue. This phenomenon is called enhanced permeability and retention (EPR).Active targeting involves the recognition of nanoparticles by the tumor cell surface receptors. This will enhance the sensitivity of in vivo tumor detection. For early detection of cancer, active targeting will give better results than passive targeting [16-18].

This can be classified as delivery of chemotherapy, immunotherapy, radiotherapy, and gene therapy, and delivery of chemotherapy is aimed at improving the pharmacokinetics and reducing drug toxicity by selective targeting and delivery to cancer tissues. This is primarily based on passive targeting, which employs the EPReffect described earlier [16]. Nanocarriers increase the half-life of the drugs. Immunotherapy is a promising new front in cancer treatment based on understanding the tumor-host interaction. Nanotechnology is being investigated to deliver immunostimulatory or immunomodulatory molecules. It can be used as an adjuvant to other therapies [19-21].

Role of Nanotechnology in Radiotherapy

Thistechnology involves targeted delivery of radioisotopes, targeted delivery of radiosensitizer, reduced side effects of radiotherapy by decreasing distribution to healthy tissues, and combining radiotherapy with chemotherapy to achieve synergism but avoid side effects, andadministering image-guided radiotherapy improves precision and accuracy while reducing exposure to surrounding normal tissues[22,23].

Gene Therapy Using Nanotechnology

There is a tremendous interest in the research in gene therapy for cancer, but the results are still falling short of clinical application. Despite a wide array of therapies aimed at gene modulation, such as gene silencing, anti-sense therapy, RNAinterference, and gene and genome editing, finding a way to deliver these effects is challenging. Nanoparticles are used as carriers for gene therapy, with advantages such as easy construction and functionalizing and low immunogenicity and toxicity. Gene-targeted delivery using nanoparticles has great future potential. Gene therapy is still in its infancy but is very promising [24].

Nanodelivery Systems

Quantum dots: Semiconductor nanocrystal quantum dots (QDs) have outstanding physical properties. Probes based on quantum dots have achieved promising cellular and in vivo molecular imaging developments. Increasing research is proving that technology based on quantum dots may become an encouraging approach in cancer research[4]. Biocompatible QDs were launched for mapping cancer cells in vitro in 1998. Scientists used these to create QD-based probes for cancer imaging that were conjugated with cancer-specific ligands, antibodies, or peptides. QD-immunohistochemistry (IHC) has more sensitivity and specificity than traditional immunohistochemistry (IHC) and can accomplish measurements of even low levels, offering considerably higher information for individualized management. Imaging utilizing quantum dots has emerged as a promising technology for early cancer detection[25,26].

Nanoshells and gold nanoparticles/gold nanoshells (AuNSs) are an excellent example of how combining nanoscience and biomedicine can solve a biological problem. They have an adjustable surface plasmon resonance, which can be set to the near-infrared to achieve optimal penetration of tissues. During laser irradiation, AuNSs' highly effective light-to-heat transition induces thermal destruction of the tumor without harming healthy tissues. AuNSs can even be used as a carrier for a wide range of diagnostic and therapeutic substances[27].

Dendrimers: These are novel nanoarchitectures with distinguishing characteristics such as a spherical three-dimensional shape, a monodispersed uni-micellar nature, and a nanometric size range. The biocompatibility of dendrimers has been employed to deliver powerful medications such as doxorubicin. This nanostructure targets malignant cells by attaching ligands to their surfaces. Dendrimers have been intensively investigated for targeting and delivering cancer therapeutics and magnetic resonance imaging contrast agents. The gold coating on its surface significantly reduced their toxicity without significantly affecting their size. It also served as an anchor for attaching high-affinity targeting molecules to tumor cells [28].

Liposomal nanoparticles (Figure 1): These have a role in delivery to a specific target spot, reducing biodistribution toxicity because of the surface-modifiable lipid composition, and have a structure similar to cell membranes. Liposome-based theranostics (particles constructed for the simultaneous delivery of therapeutic and diagnostic moieties) have the advantage of targeting specific cancer cells.Liposomes are more stable in the bloodstream and increase the solubility of the drug. They also act as sustained release preparations and protect the drug from degradation and pH changes, thereby increasing the drug's circulating half-life. Liposomes help to overcome multidrug resistance. Drugs such as doxorubicin, daunorubicin, mitoxantrone, paclitaxel, cytarabine, and irinotecanare used with liposome delivery [29-31].

Polymeric micelles: Micelles are usually spherical particles with a diameter of 10-100 nm, which are self-structured and have a hydrophilic covering shell and a hydrophobic core, suspended in an aqueous medium. Hydrophobic medicines can be contained in the micelle's core. A variety of molecules having the ability to bind to receptors, such as aptamers, peptides, antibodies, polysaccharides, and folic acid, are used to cover the surface of the micelle in active tumor cell targeting. Enzymes, ultrasound, temperature changes, pH gradients, and oxidationare used as stimuli in micelle drug delivery systems. Various physical and chemical triggers are used as stimuli in micelle drug delivery systems. pH-sensitive polymer micelle is released by lowering pH. A co-delivery system transports genetics, as well as anticancer medicines. Although paclitaxel is a powerful microtubule growth inhibitor, it has poor solubility, which causes fast drug aggregation and capillary embolisms. Such medicines' solubility can beraised to 0.0015-2 mg/ml by encapsulating them in micelles. Polymeric micelles are now being tested for use in nanotherapy [32].

Carbon nanotubes (CNTs): Carbon from burned graphite is used to create hollow cylinders known as carbon nanotubes (CNTs). They possess distinct physical and chemical characteristics that make them interesting candidates as carriers of biomolecules and drug delivery transporters. They have a special role in transporting anticancer drugs with a small molecular size. Wu et al. formed amedicine carrier system using multi-walled CNTs (MWCNTs) and the 10-hydroxycamptothecin (HCPT) anticancer compound. As a spacer between MWCNTs and HCPT, they employed hydrophilic diamine trimethylene glycol. In vitro and in vivo, their HCPT-MWCNT conjugates showed significantly increased anticancer efficacy when compared to traditional HCPTformulations. These conjugates were able to circulate in the blood longer and were collected precisely at the tumor site [33,34].

Limitations

Manufacturing costs, extensibility, safety, and the intricacy of nanosystems must all be assessed and balanced against possible benefits. The physicochemical properties of nanoparticles in biological systems determine their biocompatibility and toxicity. As a result, stringent manufacturing and delineation of nanomaterials for delivery of anticancer drugs are essential to reduce nanocarrier toxicity to surrounding cells. Another barrier to medication delivery is ensuring public health safety, as issues with nanoparticles do not have an immediate impact. The use of nanocarriers in cancer treatment may result in unforeseen consequences. Hypothetical possibilities of environmental pollution causing cardiopulmonary morbidity and mortality, production of reactive oxygen species causing inflammation and toxicity, and neuronal or dermal translocations are a few possibilities that worry scientists. Nanotoxicology, a branch of nanomedicine, has arisen as a critical topic of study, paving the way for evaluating nanoparticle toxicity [35-37].

Nanotechnology has been one of the recent advancements of science that not only has revolutionized the engineering field but also is now making its impact in the medical and paramedical field. Scientists have been successful in knowing the properties and characteristics of these nanomaterials and optimizing them for use in the healthcare industry. Although some nanoparticles have failed to convert to the clinic, other new and intriguing nanoparticles are now in research and show great potential, indicating that new treatment options may be available soon. Nanomaterials are highly versatile, with several benefits that can enhance cancer therapies and diagnostics.

These are particularly useful as drug delivery systems due to their tiny size and unique binding properties. Drugs such as doxorubicin, daunorubicin, mitoxantrone, paclitaxel, cytarabine, irinotecan, and amphotericin B are already being conjugated with liposomes for their delivery in current clinical practices. Doxorubicin, cytarabine, vincristine, daunorubicin, mitoxantrone, and paclitaxel, in particular, are key components of cancer chemotherapy. Even in the diagnosis of cancer for imaging and detection of tumor markers, particles such as nanoshells, dendrimers, and gold nanoparticles are currently in use.

Limitations of this novel technology include manufacturing expenses, extensibility, intricacy, health safety, and potential toxicity. These are being overcome adequately by extensive research and clinical trials, and nanomedicine is becoming one of the largest industries in the world. A useful collection of research tools and clinically practical gadgets will be made available in the near future thanks to advancements in nanomedicine. Pharmaceutical companies will use in vivo imaging, novel therapeutics, and enhanced drug delivery technologies in their new commercial applications. In the future, neuro-electronic interfaces and cell healing technology may change medicine and the medical industry when used to treat brain tumors.

Continue reading here:
The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus

Posted in Nano medicine | Comments Off on The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review – Cureus

International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. – ETHealthWorld

Posted: September 16, 2022 at 2:56 am

Chennai, September 16, 2022: The International Conference on Advances in Molecular Diagnostics and Precision Medicine (AMDP) began on 15th September 2022 at Anna University, Chennai and will continue till 17th September. The conference revolves around various facets of Molecular Diagnostics and Precision Medicine as the major area and Drug discovery and Development and Nanotechnology as parallel sessions. The conference has attracted over 800 delegates that include experts from the field of Molecular Diagnostics, Personalized Cancer Therapies, Infectious Diseases, Rare Diseases, Bio-Nanotechnology, etc. Apart from insights from some of the best minds in medicine and medical technology, the conference also hosts investors who are interested to explore emerging technologies.

AMDP 2022 also witnesses product launches by MagGenome Technologies Pvt Ltd. They have specifically strengthened the sector of medical diagnostics by launching XpressAutoMag range of products for DNA and RNA extraction from biological samples. These unique products will fill the gap in the current market by providing DNA extraction using MagGenomes proprietary Magnetic Nano Particle (MNP) technology that will improve efficiency, and reduce time and cost for the general public. This has applications in doing faster tests for the general public as well as for large-scale industries.

DNA and RNA extraction using MNP technology will improve yield, purity and quality in comparison to the currently existing solutions in India. Additionally, MagGenomes flexible, automated nucleic acid extraction platform will provide stable and reproducible results at a low cost. This technology will effectively avoid cross-contamination and ensure high quality of extracted nucleic acids and will further enhance global applications in research and diagnostic capabilities in the field of molecular diagnostics and genomics. This will also strengthen Made in India products for the World in the clinical diagnostics sector. Several speakers and participants from Life Sciences and Diagnostics companies like MagGenome Technologies Pvt Ltd, KMTC, KLIP, Genes2me, Neuberg diagnostics, Nanostrings, Premas Biotech, Levim Biotech, SPT Labtech, ThermoFisher Scientific, Bioengineering, GenNext Genomics Pvt Ltd., iOrbitz and Institutes like CCMB, IGIB, NCBS, CDFD, AIIMS, and CHARUSAT will attend the event. The Patron of the conference is Mr.Sam Santhosh. Dr.CN Ramchand and Dr.S Meenakshi Sundaram are the Conference Conveners and Dr.Aniruddha Bhati is the Organising Secretary.

The Conference will also provide student scholarships, poster awards, young scientist awards and lifetime achievement awards to deserving candidates and proven performers in the field.

Originally posted here:
International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld

Posted in Nano medicine | Comments Off on International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. – ETHealthWorld

Page 211«..1020..210211212213..220230..»